Sanford Markowitz
Corporate Officer/Principal chez Case Western Reserve University School of Medicine
Profil
Sanford Markowitz was the founder of Rodeo Therapeutics Corp.
which was founded in 2017, where he held the title of Director.
Currently, he is a Professor at Case Western Reserve University School of Medicine since 1988.
Previously, he was a Director at Lucid Diagnostics, Inc. Dr. Markowitz received his undergraduate degree from Harvard University and his doctorate from Yale University.
Postes actifs de Sanford Markowitz
| Sociétés | Poste | Début |
|---|---|---|
| Case Western Reserve University School of Medicine | Corporate Officer/Principal | 01/01/1988 |
Anciens postes connus de Sanford Markowitz
| Sociétés | Poste | Fin |
|---|---|---|
| LUCID DIAGNOSTICS INC. | Directeur/Membre du Conseil | - |
Rodeo Therapeutics Corp.
 Rodeo Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Rodeo Therapeutics Corp. engages in the development of drugs. The firm develops novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant. It focuses on the development of small-molecule therapies that increase tissue levels of prostaglandin PGE2. The company was founded by Stanton Gerson, Sanford Markowitz, and Joseph Ready on May 15, 2017 and is headquartered in Seattle, WA. | Fondateur | - |
Formation de Sanford Markowitz
| Harvard University | Undergraduate Degree |
| Yale University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| LUCID DIAGNOSTICS INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Rodeo Therapeutics Corp.
Rodeo Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Rodeo Therapeutics Corp. engages in the development of drugs. The firm develops novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant. It focuses on the development of small-molecule therapies that increase tissue levels of prostaglandin PGE2. The company was founded by Stanton Gerson, Sanford Markowitz, and Joseph Ready on May 15, 2017 and is headquartered in Seattle, WA. | Health Technology |
